Abciximab therapy in percutaneous intervention: Economic issues in the United States
- 1 April 1998
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 135 (4) , s90-s97
- https://doi.org/10.1016/s0002-8703(98)70301-1
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Safe use of platelet GP IIb/IIIa inhibitorsAmerican Heart Journal, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary AngioplastyCirculation, 1996
- Relation Between Activated Clotting Time During Angioplasty and Abrupt ClosureCirculation, 1996
- Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary InterventionCirculation, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Effects of Coronary Angioplasty, Coronary Bypass Surgery, and Medical Therapy on Employment in Patients with Coronary Artery Disease: A Prospective Comparison StudyAnnals of Internal Medicine, 1994
- Direct and Indirect Cost of Percutaneous Transluminal Coronary AngioplastyCardiology, 1994
- Three days of heparin pretreatment reduces major complications of coronary angioplasty in patients with unstable anginaJournal of the American College of Cardiology, 1990